Abstract

ANALYSIS OF MODIFICATIONS IN TREATMENTS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN A UNIVERSITY HOSPITAL

Julia San Miguel Rodríguez, María San Miguel Rodríguez, María Julita Rodríguez

.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system producing neurological lesions. A retrospective observational study has been carried out in patients with RRMS who underwent a change in treatment of FME between january and december 2020. A total of 22 patients from the HURH hospital with RRMS were found who underwent a change in treatment. Of the total of patients, 17 (77.3%) were women and 5 (22.7%) were men. The main reason for changing treatment in patients with RRMS in HURH has been due to therapeutic failure (59.1%) followed by the appearance of adverse effects (36.4%) and the desire for pregnancy. At the time of the change, more than 90% of the patients were in treatment with first-line drugs Interferon β, Glatiramer acetate, Dimethyl fumarate and Teriflunomide. Most of the adverse effects (50%) were due to puncture and skin intolerance with interferon β, the majority being change to Dimethyl fumarate for oral administration. In therapeutic failure with disease progression, a therapeutic escalation was carried out, using second-line EMFs of higher potency, oral fingolimod and intravenous ocrelizumab.

Keywords: Multiple sclerosis, Treatment, Relapsing remitting multiple treatment, Interferon ?, Glatiramer acetate, Dimethyl fumarate, Teriflunomide.